Page results
-
This information is for patients, (and their family and carers), who are considering having Uterine Artery (Fibroid) Embolisation (UAE). It explains what is involved and the possible risks.
-
UCLH has been selected as the lead site in Great Britain for Neuralink’s GB-PRIME study, a clinical investigation for Neuralink’s brain-computer interface (BCI).
-
It is important to make sure you are eating and drinking well before your surgery. Good nutrition will also help you recover after your surgery.
-
This information is for patients who have attended the emergency department with an undisplaced or minimally displaced fracture (broken bone) at the base of your 5th metatarsal.
-
Tasnim tells us about her experience training with the Pharmacy team at UCLH and how their support has encouraged her to pursue this career.
-
Today we are launching the new UCLH strategy for 2023-2027. Developed with staff, patients and key partners, the strategy sets the future direction of UCLH over the next five years.
-
This page has been written for patients who are having a course of superficial radiotherapy for a skin tumour (such as a basal cell carcinoma or squamous cell carcinoma), or some other skin condition.
-
This page is for patients who are having stereotactic ablative body radiotherapy (SABR) for lung cancer.
-
This information has been written to help you now that your radiotherapy treatment is finishing.
-
This page has been written for parents and carers whose child is having radiotherapy treatment to the neck, chest, abdomen, and pelvis.
File results
-
FOI/2021/0696 - Procurement of Robotic Process Automation (RPA)
-
FOI/2021/0704 - Language translation and interpreting services
-
FOI/2021/0708 - Treatment of dermatological conditions
-
FOI/2021/0713 - Incidence and treatment of Haemophilia A
-
FOI/2021/0714 - Data management systems of care testing devices
-
FOI/2021/0715 - Urothelial cancer treatment
-
FOI/2021/0716 - COVID-19 deaths
-
FOI/2021/0721 - Maternity units within your trust
-
FOI/2021/0723 - Covid 19 deaths
-
FOI/2021/0730 - Treatment with Ofatumumab